Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

The improvement of intestinal dysbiosis and hepatic metabolic dysfunction in dextran sulfate sodium-induced colitis mice: effects of curcumin

Graphical Abstract Sample Work

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic inflammatory condition with increasing global prevalence and limited long-term therapeutic success. Conventional treatments are often associated with suboptimal response and adverse effects, prompting interest in safer adjunct therapies. Curcumin, a natural polyphenol derived from Curcuma longa, exhibits potent anti-inflammatory, antioxidant, and immunomodulatory properties and has shown beneficial effects in experimental and clinical IBD studies. However, clinical outcomes remain inconsistent and the mechanisms of action are not fully understood. This study examines current evidence on curcumin’s efficacy, safety, and mechanistic role in IBD management.

An experimental workflow that reads left to right

This graphical abstract summarises a mouse study by Zhou and colleagues, published in the Journal of Gastroenterology and Hepatology in 2023, on how curcumin affects intestinal dysbiosis and liver metabolism in dextran sulfate sodium (DSS)-induced colitis. The paper links two organs and several omics methods, so its figure has to show an experimental pipeline as well as results from two separate tissues. It is designed for gastroenterology and hepatology researchers, nutrition scientists and pharmacology teams interested in gut–liver interactions.

The canvas is divided into four vertical zones of increasing colour depth: the animal model, the analytical methods, the intestinal findings and the hepatic findings. That progression from pale to dark green gives the eye a natural reading order without numbered steps.

Why look at the liver in a colitis model?

Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a chronic relapsing inflammatory condition whose prevalence is rising worldwide. Current treatments do not help every patient and can cause adverse effects, which keeps interest high in adjunct therapies. Curcumin, a polyphenol from Curcuma longa, has anti-inflammatory, antioxidant and immunomodulatory properties and has shown benefit in some experimental and clinical IBD studies, although clinical results have been inconsistent and its mechanisms are not settled.

The gut and liver are connected through the portal circulation and through bile acids, which the liver produces and gut bacteria modify. Disturbed gut microbiota can therefore alter hepatic metabolism, and liver dysfunction is a recognised extra-intestinal feature of IBD. A study that measures both the microbiome and the liver metabolome can ask whether curcumin acts across this axis rather than in the colon alone.

Zone one and two: model and methods

The leftmost zone shows the experimental design in three icons: mice receive 2% DSS to induce colitis and are then treated with curcumin (CUR), with group size stated as N = 8 per group. A single arrow leads to a vertical bracket listing the analyses performed, each paired with a small image of the technique:

  • HE (haematoxylin and eosin) staining for colonic histology;
  • 16S rDNA MiSeq sequencing of the gut microbiota;
  • 1H-NMR spectroscopy and LC-MS for metabolite profiling;
  • SCC analysis, shown as a heatmap, to correlate microbial and metabolic features.

Showing the instruments as thumbnails is an efficient way to tell readers that this is a multi-platform study without writing out the protocol.

Zone three and four: what changed in the gut and in the liver

The intestinal microecology panel lists findings under three subheadings, each with upward arrows. At genus level, Akkermansia, Muribaculum and unclassified Muribaculaceae increased. Faecal short-chain fatty acids (SCFAs) and amino acids increased, along with glycolysis/gluconeogenesis and amino acid metabolism pathways.

The hepatic metabolism panel, linked to the gut panel by a double-headed arrow representing the gut–liver axis, lists enriched pathways: AMPK, cAMP, glucagon, biotin, phenylalanine, tyrosine and tryptophan biosynthesis, secondary and primary bile acid biosynthesis, and butanoate metabolism. Two liver metabolites are highlighted as increased: anthranilic acid and 8-amino-7-oxononanoate.

The bile acid and butanoate entries are worth noticing because they connect the two panels biologically: butanoate (butyrate) is an SCFA produced by gut bacteria, and secondary bile acids are formed by microbial metabolism of primary bile acids made in the liver.

Choices that suit an animal omics study

Several design decisions in the figure reflect good practice for preclinical work. The group size appears beside the model, which supports transparent reporting in the spirit of the ARRIVE guidelines for animal research. Taxon names are italicised, as nomenclature conventions require. Arrows are used only for direction of change after treatment; the figure does not add effect sizes it cannot justify in a small space. The full citation with DOI runs along the bottom.

One limitation of list-style results panels is that they can look like text slides. Here, the organ illustrations, the faecal pellet with a zoomed molecular structure and the colour zoning keep the panels visual.

Adapting the structure for microbiome and metabolomics papers

Researchers with gut–organ axis data can reuse this four-zone pattern: model, methods, organ one, organ two, with a linking arrow carrying the mechanistic hypothesis. Keep the findings to those the paper's abstract emphasises, and preserve species and pathway names exactly as reported.

Pubrica's graphical abstract service designs figures from submitted manuscripts, and the same content can be adapted into a simplified abstract for readers outside the field. For studies still at the planning stage, experimental design support can address group sizes and analysis plans before the work begins.

Questions about this sample

Does this graphical abstract show that curcumin treats IBD in people?

No. The figure summarises a study in mice with colitis induced by 2% dextran sulfate sodium. It shows changes in gut bacteria, faecal metabolites and liver metabolic pathways after curcumin treatment in that model. Animal findings like these generate hypotheses but do not establish clinical efficacy in patients with Crohn's disease or ulcerative colitis.

Why does the figure highlight Akkermansia and Muribaculum?

These genera increased after curcumin treatment in the study and are commonly discussed in relation to intestinal barrier function and microbial metabolism. Placing them at the top of the intestinal panel signals that changes in microbial composition are the starting point for the gut–liver effects shown in the rest of the figure.

What does the double-headed arrow between the gut and liver panels represent?

It represents the gut–liver axis, the two-way relationship in which gut microbes and their metabolites reach the liver through the portal circulation and liver-derived bile acids return to the intestine. The bile acid and butanoate pathways listed in the liver panel make this connection concrete.

pubrica services with experts

Research your Services with our experts

Delivered on-time or your money back

Give yourself the academic edge today

Each order includes

  • On-time delivery or your money back
  • A fully qualified writer in your subject
  • In-depth proofreading by our Quality Control Team
  • 100% confidentiality, the work is never re-sold or published
  • Standard 7-day amendment period
  • A paper written to the standard ordered
  • A detailed plagiarism report
  • A comprehensive quality report

Enquire Now

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.